KR20210102204A - 면역 조절 폴리뉴클레오타이드 컨쥬게이트 및 사용 방법 - Google Patents
면역 조절 폴리뉴클레오타이드 컨쥬게이트 및 사용 방법 Download PDFInfo
- Publication number
- KR20210102204A KR20210102204A KR1020217014643A KR20217014643A KR20210102204A KR 20210102204 A KR20210102204 A KR 20210102204A KR 1020217014643 A KR1020217014643 A KR 1020217014643A KR 20217014643 A KR20217014643 A KR 20217014643A KR 20210102204 A KR20210102204 A KR 20210102204A
- Authority
- KR
- South Korea
- Prior art keywords
- conjugate
- seq
- group
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(C(N)=N1)=CN(*)C1=O Chemical compound *C(C(N)=N1)=CN(*)C1=O 0.000 description 21
- STOYRPKFTJIVEM-UHFFFAOYSA-N CCc(cc1)ccc1-c1nnc(C)nn1 Chemical compound CCc(cc1)ccc1-c1nnc(C)nn1 STOYRPKFTJIVEM-UHFFFAOYSA-N 0.000 description 2
- FEHUTHGOLLQBNW-UHFFFAOYSA-N CC(C)N(C(C)C)P(N(C(C)C)C(C)C)Cl Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)Cl FEHUTHGOLLQBNW-UHFFFAOYSA-N 0.000 description 1
- PDKSWOKPIJYGIH-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCC#N)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(F)(F)F)C(N1)=O)C1=O Chemical compound CC(C)N(C(C)C)P(OCCC#N)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(F)(F)F)C(N1)=O)C1=O PDKSWOKPIJYGIH-UHFFFAOYSA-N 0.000 description 1
- SCTZFNBNTRINTJ-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(N1)=O)Br)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(N1)=O)Br)C1=O SCTZFNBNTRINTJ-UHFFFAOYSA-N 0.000 description 1
- ZGEHFKOKTCLGKW-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(N1)=O)I)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(N1)=O)I)C1=O ZGEHFKOKTCLGKW-UHFFFAOYSA-N 0.000 description 1
- GISGAESWMACHIA-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(NC1OC1C)=N1)I)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C(NC1OC1C)=N1)I)C1=O GISGAESWMACHIA-UHFFFAOYSA-N 0.000 description 1
- GRVRSYFRQZKMCY-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C)C(N1)=O)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C)C(N1)=O)C1=O GRVRSYFRQZKMCY-UHFFFAOYSA-N 0.000 description 1
- UZLHTWFDFZCKMY-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C1NNN(C)C1)C(N1)=O)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C1NNN(C)C1)C(N1)=O)C1=O UZLHTWFDFZCKMY-UHFFFAOYSA-N 0.000 description 1
- ILUQEKMNMSOBIQ-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C1NNNC1)C(N1)=O)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C1NNNC1)C(N1)=O)C1=O ILUQEKMNMSOBIQ-UHFFFAOYSA-N 0.000 description 1
- YRNYNQSEKFPWMZ-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C1SCCN1)C(N1)=O)C1=O Chemical compound CC(C)N(C(C)C)P(OCCCN)OC(C1)C(COC(c2ccccc2)(c(cc2)ccc2OC)c(cc2)ccc2OC)OC1N(C=C(C1SCCN1)C(N1)=O)C1=O YRNYNQSEKFPWMZ-UHFFFAOYSA-N 0.000 description 1
- FSRJZWIBZLVSGK-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCc(cccc1)c1SSC(C)(C)C)OCCC#N Chemical compound CC(C)N(C(C)C)P(OCCc(cccc1)c1SSC(C)(C)C)OCCC#N FSRJZWIBZLVSGK-UHFFFAOYSA-N 0.000 description 1
- PWUNADHIAAMZCA-UHFFFAOYSA-N CC(Cc(cc1)ccc1-c1nnc(C)nn1)=O Chemical compound CC(Cc(cc1)ccc1-c1nnc(C)nn1)=O PWUNADHIAAMZCA-UHFFFAOYSA-N 0.000 description 1
- RSDMYGZEJVXPED-UHFFFAOYSA-N CCC(C)CN=C Chemical compound CCC(C)CN=C RSDMYGZEJVXPED-UHFFFAOYSA-N 0.000 description 1
- RWRZAESQRPSFAA-UHFFFAOYSA-N CCCCOP(N(C(C)C)C(C)C)OCC(COC(c1ccccc1)(c(cc1)ccc1OC)c(cc1)ccc1OC)OCC#C Chemical compound CCCCOP(N(C(C)C)C(C)C)OCC(COC(c1ccccc1)(c(cc1)ccc1OC)c(cc1)ccc1OC)OCC#C RWRZAESQRPSFAA-UHFFFAOYSA-N 0.000 description 1
- YESRPUBJQJUUAW-UHFFFAOYSA-N CNCC1C(CC2)C1CCc1c2nn[n]1C Chemical compound CNCC1C(CC2)C1CCc1c2nn[n]1C YESRPUBJQJUUAW-UHFFFAOYSA-N 0.000 description 1
- SVXACWHDMWQWEC-UHFFFAOYSA-N COc1ccc(C(c2ccccc2)(c(cc2)ccc2OC)OCC(CO)OCC#C)cc1 Chemical compound COc1ccc(C(c2ccccc2)(c(cc2)ccc2OC)OCC(CO)OCC#C)cc1 SVXACWHDMWQWEC-UHFFFAOYSA-N 0.000 description 1
- BWKDAAFSXYPQOS-UHFFFAOYSA-N OC1COC(c2ccccc2)OC1 Chemical compound OC1COC(c2ccccc2)OC1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747070P | 2018-10-17 | 2018-10-17 | |
| US62/747,070 | 2018-10-17 | ||
| US201862747611P | 2018-10-18 | 2018-10-18 | |
| US62/747,611 | 2018-10-18 | ||
| PCT/US2019/056619 WO2020081744A1 (en) | 2018-10-17 | 2019-10-16 | Immunomodulating polynucleotide conjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210102204A true KR20210102204A (ko) | 2021-08-19 |
Family
ID=70284225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217014643A Ceased KR20210102204A (ko) | 2018-10-17 | 2019-10-16 | 면역 조절 폴리뉴클레오타이드 컨쥬게이트 및 사용 방법 |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| MX2024002187A (es) * | 2021-08-20 | 2024-03-12 | Tallac Therapeutics Inc | Anticuerpos y conjugados de nectina-4. |
| TW202328185A (zh) * | 2021-08-25 | 2023-07-16 | 美商泰勒克療法公司 | SIRP-α抗體及結合物 |
| WO2023081934A1 (en) * | 2021-11-08 | 2023-05-11 | The University Of Chicago | Methods and compositions for pkc-delta inhibition and cancer immunotherapy |
| KR20250039518A (ko) * | 2022-05-18 | 2025-03-20 | 탈락 테라퓨틱스, 인크. | 항-cd22 항체 올리고뉴클레오타이드 접합체를 사용하여 암을 치료하는 방법 |
| AU2025211114A1 (en) * | 2024-01-24 | 2026-06-18 | F. Hoffmann-La Roche Ag | Linkers for site-specific protein conjugation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| CN107109405A (zh) * | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| US20180134802A1 (en) * | 2016-01-08 | 2018-05-17 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same |
| JP2019513692A (ja) * | 2016-02-19 | 2019-05-30 | ジェニスフィア・エルエルシー | 核酸キャリア及び治療上の使用方法 |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
-
2019
- 2019-10-16 AU AU2019360216A patent/AU2019360216A1/en active Pending
- 2019-10-16 CA CA3116880A patent/CA3116880A1/en active Pending
- 2019-10-16 MX MX2021004365A patent/MX2021004365A/es unknown
- 2019-10-16 WO PCT/US2019/056619 patent/WO2020081744A1/en not_active Ceased
- 2019-10-16 CN CN201980082021.3A patent/CN113660955A/zh active Pending
- 2019-10-16 IL IL282282A patent/IL282282B2/en unknown
- 2019-10-16 SG SG11202103805SA patent/SG11202103805SA/en unknown
- 2019-10-16 US US17/283,919 patent/US20220096649A1/en not_active Abandoned
- 2019-10-16 EP EP19874575.4A patent/EP3866858A4/en active Pending
- 2019-10-16 KR KR1020217014643A patent/KR20210102204A/ko not_active Ceased
- 2019-10-16 BR BR112021007294-2A patent/BR112021007294A2/pt unknown
- 2019-10-16 JP JP2021546200A patent/JP7536025B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7536025B2 (ja) | 2024-08-19 |
| IL282282B1 (en) | 2025-03-01 |
| BR112021007294A2 (pt) | 2021-07-27 |
| IL282282A (en) | 2021-05-31 |
| JP2022508825A (ja) | 2022-01-19 |
| EP3866858A4 (en) | 2022-10-26 |
| US20220096649A1 (en) | 2022-03-31 |
| CN113660955A (zh) | 2021-11-16 |
| SG11202103805SA (en) | 2021-05-28 |
| IL282282B2 (en) | 2025-07-01 |
| MX2021004365A (es) | 2021-07-06 |
| AU2019360216A1 (en) | 2021-05-13 |
| CA3116880A1 (en) | 2020-04-23 |
| WO2020081744A1 (en) | 2020-04-23 |
| EP3866858A1 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7536025B2 (ja) | 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 | |
| JP7751590B2 (ja) | トランスグルタミナーゼ媒介コンジュゲーション | |
| JP7384835B2 (ja) | Cd3に特異的な抗体及びその使用 | |
| US12378313B2 (en) | Bispecific binding agents binding to CLDN18.2 and CD3 | |
| CN108350082A (zh) | Pd-l1抗体及其用途 | |
| JP2019503661A (ja) | Cd3とcd38とを結合するヘテロ二量体抗体 | |
| EP3529268A1 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| US20240228645A1 (en) | Antibodies targeting baff-r and use thereof | |
| WO2019195408A1 (en) | Antibody variable domains targeting dll3, and use thereof | |
| WO2022216723A9 (en) | Bispecific antibodies targeting nkp46 and cd38 and methods of use thereof | |
| TW202328185A (zh) | SIRP-α抗體及結合物 | |
| JP2023510986A (ja) | 疾患の治療に使用するための多重特異性抗体 | |
| JP2024531382A (ja) | ネクチン-4抗体およびコンジュゲート | |
| WO2025179294A2 (en) | Immune engineering amplification | |
| JP2024536133A (ja) | 抗hsp70抗体およびその治療的使用 | |
| WO2024206126A1 (en) | Cd16-binding antibodies and uses thereof | |
| CN117836413A (zh) | 连接蛋白-4抗体和缀合物 | |
| WO2024206329A1 (en) | Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof | |
| JP2024518843A (ja) | 抗icos抗体の使用 | |
| WO2026085393A2 (en) | T cell engager antibody-drug conjugates | |
| HK1259426B (en) | Anti-pd-l1 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |